With a market cap of $384.6 billion, AbbVie Inc. (ABBV) is a global research-driven pharmaceutical company that develops and markets advanced therapies across immunology, oncology, neuroscience, and aesthetics. The Illinois-based company is known for blockbuster drugs like Humira and newer growth drivers such as Skyrizi and Rinvoq.
The drug giant is expected to announce its fiscal first-quarter earnings for 2026 on Friday, Apr. 24, before the market opens. Ahead of the event, analysts expect ABBV to report a profit of $3.01 per share on a diluted basis, up 22.4% from $2.46 per share in the year-ago quarter. The company has consistently surpassed Wall Street’s EPS estimates in its last four quarterly reports.
For the current year, analysts expect ABBV to report EPS of $14.59, up 45.9% from $10 in fiscal 2025. Its EPS is expected to rise 10.6% year over year to $16.14 in fiscal 2027.
ABBV stock has climbed 4.2% over the past 52 weeks, lagging behind the S&P 500 Index’s ($SPX) 16.7% gains but surpassing the State Street Health Care Select Sector SPDR Fund’s (XLV) 3.1% returns over the same time frame.
On Mar. 27, AbbVie Inc. announced new dermatology research at the 2026 American Academy of Dermatology Annual Meeting, presenting 24 abstracts that highlight strong clinical and real-world evidence for its key drugs, risankizumab and upadacitinib. The data demonstrated sustained efficacy, long-term safety, and improved quality of life in treating immune-mediated skin diseases, reinforcing AbbVie’s leadership in dermatology and commitment to advancing treatment standards. Following the announcement, the company’s shares rose about 1.8% in the next trading session.
Analysts’ consensus opinion on ABBV stock is moderately bullish, with a “Moderate Buy” rating overall. Out of 31 analysts covering the stock, 17 advise a “Strong Buy” rating, two suggest a “Moderate Buy,” and 12 give a “Hold.” ABBV’s average analyst price target is $249.82, indicating a potential upside of 16.2% from the current levels.
On the date of publication, Kritika Sarmah did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.
More news from Barchart
